Fisher Asset Management, LLC’s Tg Therapeutics Inc (TGTX) position
Reported position history, portfolio importance and verified filing changes from public SEC disclosures.
At a glance
The full verified relationship, including prior ownership episodes and exits where supported.
Fisher Asset Management, LLC first reported Tg Therapeutics Inc in Q3 2021. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Fisher Asset Management, LLC sold the entire position in Q2 2022, and the stock is no longer reported in the latest verified portfolio.
Position over time
See the same verified relationship through reported shares, portfolio weight or reported value.
Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.
What changed
Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.
Filing context
Quarter-end price $9.51
Filing context
Quarter-end price $19.00
Filing context
Quarter-end price $33.28
How important was Tg Therapeutics Inc in Fisher Asset Management, LLC’s reported portfolio?
Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.
SEC filing evidence
Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.
Market context only; not an investor transaction price.
Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Fisher Investments’ complete global portfolio, client mandates, short positions, exact trade dates or execution prices. Options are reported separately.